Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Up 4.8%

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) shot up 4.8% during mid-day trading on Tuesday . The stock traded as high as $19.00 and last traded at $18.86. 83,765 shares traded hands during trading, a decline of 79% from the average session volume of 394,420 shares. The stock had previously closed at $18.00.

Wall Street Analyst Weigh In

Several research firms recently issued reports on KNSA. Evercore ISI upped their price target on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Wells Fargo & Company assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, May 3rd. They issued an “overweight” rating and a $34.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, April 23rd. Finally, JPMorgan Chase & Co. increased their target price on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $31.00.

Kiniksa Pharmaceuticals Price Performance

The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of 173.65 and a beta of 0.38. The business has a fifty day moving average price of $19.09 and a 200 day moving average price of $19.04.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 23rd. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.11). The business had revenue of $79.90 million for the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 2.78% and a negative return on equity of 7.26%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 65.4% on a year-over-year basis. During the same period last year, the business posted ($0.18) earnings per share. Research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KNSA. Schonfeld Strategic Advisors LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 180.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 208,500 shares of the company’s stock valued at $3,622,000 after purchasing an additional 134,070 shares during the period. Alps Advisors Inc. boosted its stake in Kiniksa Pharmaceuticals by 38.3% during the third quarter. Alps Advisors Inc. now owns 71,103 shares of the company’s stock valued at $1,235,000 after buying an additional 19,709 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Kiniksa Pharmaceuticals by 81.9% during the third quarter. GSA Capital Partners LLP now owns 63,216 shares of the company’s stock valued at $1,098,000 after buying an additional 28,468 shares in the last quarter. Tejara Capital Ltd boosted its stake in Kiniksa Pharmaceuticals by 3.2% during the third quarter. Tejara Capital Ltd now owns 35,000 shares of the company’s stock valued at $608,000 after buying an additional 1,069 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Kiniksa Pharmaceuticals during the fourth quarter valued at about $311,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.